Share-based legacy RSU program granted


Werte in diesem Artikel
Aktien

56.74 EUR 1.18 EUR 2.12 %


Share-based legacy RSU program granted

Novonesis’ Board of Directors has following the merger with Chr. Hansen Holding A/S ("Chr. Hansen”) today approved the continuation in 2024 of a legacy Chr. Hansen annual short-term incentive program comprising of up to 125,000 restricted share units (RSUs) for around 130 legacy Chr. Hansen key employees below the Executive Management level. Receipt of the RSUs is subject to specified KPIs and criteria supporting performance and retention. The KPIs include personal targets and financial performance indicators (such as: sales revenue, adjusted EBITDA margin, and net working capital in % of sales). Upon grant the RSUs will vest after a period of two (2) years after which participants may receive one (1) Novonesis B share per RSU. The value of the program is up to €6.7m.

Werbung


Attachment


Aktuelle Novozymes A-S (B) Aktie News

Werbung

Novozymes A-S (B) Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novozymes A-S (B) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
17.10.12 Novozymes hold Deutsche Bank AG
03.09.12 Novozymes buy ING
28.08.12 Novozymes overweight Morgan Stanley
09.08.12 Novozymes overweight Morgan Stanley
22.06.12 Novozymes overweight Morgan Stanley